Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 137 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H2 2014', provides an overview of the Peripheral T-Cell Lymphomas (PTCL)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Peripheral T-Cell Lymphomas (PTCL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral T-Cell Lymphomas (PTCL) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Peripheral T-Cell Lymphomas (PTCL)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Peripheral T-Cell Lymphomas (PTCL) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Peripheral T-Cell Lymphomas (PTCL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Peripheral T-Cell Lymphomas (PTCL) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Peripheral T-Cell Lymphomas (PTCL)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Peripheral T-Cell Lymphomas (PTCL) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Peripheral T-Cell Lymphomas (PTCL) Overview 8
Therapeutics Development 9
Pipeline Products for Peripheral T-Cell Lymphomas (PTCL) - Overview 9
Pipeline Products for Peripheral T-Cell Lymphomas (PTCL) - Comparative Analysis 10
Peripheral T-Cell Lymphomas (PTCL) - Therapeutics under Development by Companies 11
Peripheral T-Cell Lymphomas (PTCL) - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Peripheral T-Cell Lymphomas (PTCL) - Products under Development by Companies 16
Peripheral T-Cell Lymphomas (PTCL) - Companies Involved in Therapeutics Development 17
Kyowa Hakko Kirin Co., Ltd. 17
Sanofi 18
ZIOPHARM Oncology, Inc. 19
Millennium Pharmaceuticals, Inc. 20
Novartis AG 21
Eisai Co., Ltd. 22
Celgene Corporation 23
Bayer AG 24
Incyte Corporation 25
Topotarget A/S 26
Mundipharma International Limited 27
Spectrum Pharmaceuticals, Inc. 28
Chipscreen Biosciences Ltd 29
AB Science 30
Rhizen Pharmaceuticals SA 31
Peripheral T-Cell Lymphomas (PTCL) - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Target 33
Assessment by Mechanism of Action 36
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
alisertib - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
pralatrexate - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
HBI-8000 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
mogamulizumab - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
ruxolitinib phosphate - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
darinaparsin - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
masitinib - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
luminespib - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
romidepsin - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
alemtuzumab - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
forodesine hydrochloride - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
pralatrexate - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
belinostat - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
copanlisib - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
denileukin diftitox - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
TGR-1202 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
SH-7129 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Peripheral T-Cell Lymphomas (PTCL) - Recent Pipeline Updates 87
Peripheral T-Cell Lymphomas (PTCL) - Dormant Projects 127
Peripheral T-Cell Lymphomas (PTCL) - Discontinued Products 128
Peripheral T-Cell Lymphomas (PTCL) - Product Development Milestones 129
Featured News & Press Releases 129
Jul 07, 2014: FDA Grants Spectrum Pharmaceuticals Accelerated Approval of Beleodaq (belinostat) for Injection 129
Jul 03, 2014: BioAlliance Pharma Receives FDA approval for Beleodaq 130
Mar 17, 2014: Approval for Additional Indication for PTCL and CTCL of Mogamulizumab 131
Feb 06, 2014: FDA Grants Acceptance To File And Priority Review For TopoTarget A/S's Beleodaq NDA In PTCL 131
Dec 10, 2013: Spectrum Pharmaceuticals Announces Submission of New Drug Application for Belinostat, a novel pan-HDAC inhibitor 133
Dec 06, 2013: Spectrum Pharmaceuticals Highlights Abstracts On Folotyn at the 55th Annual Meeting of the American Society of Hematology 133
Dec 06, 2013: Spectrum Pharmaceuticals Highlights Abstracts On Marqibo at the 55th Annual Meeting of the American Society of Hematology 133
Aug 28, 2013: First patient dosed in part one confirmatory BelCHOP study in PTCL 134
Aug 08, 2013: Spectrum Pharmaceuticals announces postponement in filing of NDA for belinostat in PTCL to Q4 2013 134
Jul 19, 2013: Application Seeking Approval for Additional Indication for ATL, PTCL and CTCL of Mogamulizumab 135
Appendix 136
Methodology 136
Coverage 136
Secondary Research 136
Primary Research 136
Expert Panel Validation 136
Contact Us 137
Disclaimer 137

List of Tables
Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL), H2 2014 9
Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL) - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Comparative Analysis by Late Stage Development, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Development, H2 2014 15
Products under Development by Companies, H2 2014 16
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2014 17
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Sanofi, H2 2014 18
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by ZIOPHARM Oncology, Inc., H2 2014 19
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 20
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Novartis AG, H2 2014 21
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Eisai Co., Ltd., H2 2014 22
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Celgene Corporation, H2 2014 23
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Bayer AG, H2 2014 24
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Incyte Corporation, H2 2014 25
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Topotarget A/S, H2 2014 26
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Mundipharma International Limited, H2 2014 27
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2014 28
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Chipscreen Biosciences Ltd, H2 2014 29
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by AB Science, H2 2014 30
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Rhizen Pharmaceuticals SA, H2 2014 31
Assessment by Monotherapy Products, H2 2014 32
Number of Products by Stage and Target, H2 2014 35
Number of Products by Stage and Mechanism of Action, H2 2014 38
Number of Products by Stage and Route of Administration, H2 2014 40
Number of Products by Stage and Molecule Type, H2 2014 42
Peripheral T-Cell Lymphomas (PTCL) Therapeutics - Recent Pipeline Updates, H2 2014 87
Peripheral T-Cell Lymphomas (PTCL) - Dormant Projects, H2 2014 127
Peripheral T-Cell Lymphomas (PTCL) - Discontinued Products, H2 2014 128